Collaborative Arrangements and Licensing Agreements (Tables)

6 Months Ended

Jun. 30, 2022

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and six months ended June 30, 2022 and 2021, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
SPINRAZA royalties (commercial revenue)	$	59.6		$	72.2		$	113.4		$	132.2
R&D revenue		17.3			27.8			57.4			45.9
Total revenue from our relationship with Biogen	$	76.9		$	100.0		$	170.8		$	178.1
Percentage of total revenue		58	%		80	%		62	%		75	%

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and six months ended June 30, 2022 and 2021, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
R&D revenue	$	19.5		$	3.6		$	23.9		$	7.5
Percentage of total revenue		15	%		3	%		9	%		3	%